©
Oxford University Images
The agreement establishes the GSK-Oxford Cancer Immuno-Prevention Programme, aimed at exploring the potential of cancer prevention through vaccination.
The programme leverages the complementary expertise of GSK and Oxford in the science of the immune system, vaccine development and cancer biology. It is hoped that the insights generated through the programme into how cancer develops could inform new approaches to vaccination for cancer prevention, offering fresh hope in the fight against the disease.
The programme - which will be led by Professor Sarah Blagden in Oxford’s Department of Oncology, alongside Dr Timothy Clay and Dr Ramon Kemp at GSK - unites expertise from four departments across the University and builds on Oxford’s exceptional track record in vaccine development.
Professor Irene Tracey, Vice-Chancellor of the University of Oxford, said: 'This partnership represents a step forward in cancer research. By working with GSK to unite experts in clinical trials, immuno-oncology, vaccinology and precancer research from across the University of Oxford, we aim to unlock the potential of cancer vaccines and bring hope to patients worldwide.'
Read the full story on the University of Oxford website.